| Literature DB >> 35200613 |
Hyung-Ju Lim1, Joon Soo An1, Eun Seo Bae1, Eunji Cho2, Sunghoon Hwang1, Sang-Jip Nam3, Ki-Bong Oh2, Sang Kook Lee1, Dong-Chan Oh1.
Abstract
Streptomyces sp. GET02.ST and Achromobacter sp. GET02.AC were isolated together from the gut of the wharf roach, Ligia exotica, inhabiting the intertidal zone of the west coast of Korea. The co-cultivation of these two strains significantly induced the production of two new metabolites, ligiamycins A (1) and B (2), which were barely detected in the single culture of Streptomyces sp. GET02.ST. The planar structures of ligiamycins A (1) and B (2) were elucidated as new decalins coupled with amino-maleimides by the analysis of various spectroscopic data, including nuclear magnetic resonance (NMR), ultraviolet (UV), and mass (MS) data. The assignment of two nitrogen atoms in amino-maleimide in 1 was accomplished based on 1H-15N heteroatom single quantum coherence spectroscopy (HSQC) NMR experiments. The relative configurations of the ligiamycins were determined using rotating frame Overhauser effect spectroscopy (ROESY) NMR data, and their absolute configurations were deduced by comparing their experimental and calculated optical rotations. Ligiamycin A (1) displayed antibacterial effects against Staphylococcus aureus and Salmonella enterica, while ligiamycin B (2) exhibited mild cell cytotoxicity against human colorectal cancer cells.Entities:
Keywords: Achromobacter; Ligia exotica; Streptomyces; antibacterial; co-culture; cytotoxicity; decalin; maleimide; optical rotation; structure elucidation
Mesh:
Substances:
Year: 2022 PMID: 35200613 PMCID: PMC8878407 DOI: 10.3390/md20020083
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1LC/MS traces (ion counts) of ion extraction for the ion [M + H]+ at m/z 317 (ligiamycin A) (a) in a pure culture of Streptomyces sp. GET02.ST, (b) in a pure culture of Achromobacter sp. GET02.AC, and (c) in a co-culture. The LC/MS analyses were acquired with 10–100% aqueous CH3CN over 20 min.
Figure 2Structures of ligiamycins A (1) and B (2).
1H, 13C, and 15N NMR data for ligiamycins A (1) and B (2) in DMSO-d6.
| Ligiamycin A (1) a | Ligiamycin B (2) b | |||
|---|---|---|---|---|
| Position | ||||
| 1 | 165.1, C | 165.2, C | ||
| 1’ | 169.8, C | 169.9, C | ||
| 2 | 157.8, C | 157.8, C | ||
| 3 | 98.7, C | 98.7, C | ||
| 4 | 200.0, C | 200.0, C | ||
| 5 | 50.1, C | 50.1, C | ||
| 6 | 39.3, CH | 1.55, t (10.0) | 39.6, CH | 1.56, t (10.0) |
| 7a | 27.2, CH2 | 1.88, m | 26.8, CH2 | 1.92, m |
| 7b | 0.88, m c | 0.86, m | ||
| 8a | 35.7, CH2 | 1.70, m | 30.3, CH2 | 1.75, m |
| 8b | 1.00, ddd (16.0, 12.5, 3.5) | 0.99, m | ||
| 9 | 32.9, CH | 1.48, m | 40.9, CH | 1.47, m |
| 10a | 42.1, CH2 | 1.77, m | 36.8, CH2 | 1.84, m |
| 10b | 0.78, m | 0.76, m | ||
| 11 | 38.0, CH | 1.75, m | 37.7, CH2 | 1.73, m |
| 12 | 129.0, CH | 5.31, dd (10.0, 2.0) | 129.1, CH | 5.33, dd (10.0, 2.0) |
| 13 | 130.2, CH | 5.52, m | 130.2, CH | 5.52, m |
| 14 | 34.6, CH | 3.06, m | 34.6, CH | 3.06, m |
| 15 | 14.8, CH3 | 1.27, s | 14.8, CH3 | 1.28, s |
| 16 | 22.5, CH3 | 0.88, m c | 66.5, CH2 | 3.22, d (6.0) |
| 17 | 18.5, CH3 | 0.68, d (7.0) | 18.5, CH3 | 0.68, d (6.5) |
| 1,1’-NH | 146.8 d, NH | 10.6, br s | 10.6, br s | |
| 2-NH2a | 103.9 d, NH2 | 9.16, s | 9.16, s | |
| 2-NH2b | 8.90, br s | 8.89, br s | ||
| 16-OH | 4.36, br s | |||
a 1H and 13C NMR data were recorded at 800 and 200 MHz, respectively. b 1H and 13C NMR data were recorded at 850 and 225.5 MHz, respectively. c Overlapping signals. d The chemical shifts of 15N in the groups of N were determined based on the 1H-15N HSQC NMR spectrum.
Figure 3Key HMBC and COSY correlations of ligiamycins A (1) and B (2).
Figure 4Key ROESY correlations of ligiamycin A (1).
Experimental and calculated optical rotation of ligiamycins A (1) and B (2).
| Sample | Optical Rotation | ||
|---|---|---|---|
| Experimental | Calculated of | Calculated of | |
| Ligiamycin A (1) | −78 | −65 | +66 |
| Ligiamycin B (2) | −67 | −64 | +64 |
Inhibitory effects of ligiamycins against bacterial strains.
| Sample | MIC (μg/mL) | |||||
|---|---|---|---|---|---|---|
| Gram-Positive | Gram-Negative | |||||
|
|
|
|
|
|
| |
| Ligiamycin A (1) | 16 | >128 | >128 | >128 | 16 | >128 |
| Ligiamycin B (2) | 64 | >128 | >128 | >128 | >128 | >128 |
| Ampicillin | 0.13 | 0.25 | 0.5 | 128 | 0.28 | 32 |
| Tetracycline | 0.13 | 0.25 | 0.13 | 0.5 | 0.25 | 0.5 |
Inhibitory effects of ligiamycins on the proliferation of human cancer cell lines.
| IC50 (μM) | SNU638 | SK-HEP-1 | A549 | HCT116 | MDA-MB-23 |
|---|---|---|---|---|---|
| Ligiamycin A (1) | >50 | >50 | 42.0 | >50 | >50 |
| Ligiamycin B (2) | 46.2 | 34.6 | 25.9 | 20.1 | 23.7 |
| Etoposide | 2.17 | 0.24 | 0.35 | 0.66 | 2.64 |